SPR Therapeutics Inc. https://www.sprtherapeutics.com, a company involved in neuro-stimulation technology for pain management, has received two new grants and one new contract from the Department of Defense (DOD) totaling $10 million.
The funding will be used to further develop the SPRINT Peripheral Nerve Stimulation (PNS) therapy. The system offers a non-opioid pain relief therapy that is FDA cleared for treating acute and chronic pain and is the only percutaneous PNS device that is FDA cleared for both chronic and acute pain.
In addition to a previous contract and grants from NIH and DOD, the latest awards from DOD bring the total amount of grants and contracts to $30 million to be used to support the advancement of SPR Therapeutics neuro-stimulation technology for pain.
The largest award totaling $6 million will support a Randomized Controlled Trial (RCT) which will compare the SPRINT PNS System to conventional medical management used to reduce pain and opioid use while improving function for service members, veterans, and civilians experiencing chronic pain.
A second RCT supported by a $3 million grant will focus on improving pain management following surgery for combat and non-combat related orthopedic trauma. The plan is to further evaluate the use of percutaneous PNS to relieve pain, reduce or eliminate the use of opioids, and to accelerate functional recovery.
In addition, a $1 million contract supported by the Defense Health Agency’s SBIR program, will fund continued advancement of the company’s PNS platform while improving the system’s ability to support independent use by healthcare providers. The goal is to enable a wider range of interventional pain management physicians to be able to offer the system with minimal training and enable simpler self-management regarding therapy.
For more information, email Mark Stultz, Senior VP at mstultz@sprtherapeutics.com.